CA2248667C - Hla-a2.1 binding peptides and their uses - Google Patents

Hla-a2.1 binding peptides and their uses Download PDF

Info

Publication number
CA2248667C
CA2248667C CA2248667A CA2248667A CA2248667C CA 2248667 C CA2248667 C CA 2248667C CA 2248667 A CA2248667 A CA 2248667A CA 2248667 A CA2248667 A CA 2248667A CA 2248667 C CA2248667 C CA 2248667C
Authority
CA
Canada
Prior art keywords
seq
peptide
peptides
ctl
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2248667A
Other languages
English (en)
French (fr)
Other versions
CA2248667A1 (en
Inventor
Howard M. Grey
Alessandro Sette
John Sidney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2248667A1 publication Critical patent/CA2248667A1/en
Application granted granted Critical
Publication of CA2248667C publication Critical patent/CA2248667C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2248667A 1996-03-21 1997-03-21 Hla-a2.1 binding peptides and their uses Expired - Lifetime CA2248667C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1398096P 1996-03-21 1996-03-21
US82238297A 1997-03-20 1997-03-20
US60/013,980 1997-03-20
US08/822,382 1997-03-20
PCT/US1997/005348 WO1997034621A1 (en) 1996-03-21 1997-03-21 Hla-a2.1 binding peptides and their uses

Publications (2)

Publication Number Publication Date
CA2248667A1 CA2248667A1 (en) 1997-09-25
CA2248667C true CA2248667C (en) 2012-06-05

Family

ID=26685499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2248667A Expired - Lifetime CA2248667C (en) 1996-03-21 1997-03-21 Hla-a2.1 binding peptides and their uses

Country Status (9)

Country Link
EP (1) EP0907370B1 (enExample)
JP (1) JP4210735B2 (enExample)
CN (1) CN1218406A (enExample)
AT (1) ATE296313T1 (enExample)
AU (1) AU2658897A (enExample)
BR (1) BR9708220A (enExample)
CA (1) CA2248667C (enExample)
DE (1) DE69733352T2 (enExample)
WO (1) WO1997034621A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
AU6465598A (en) * 1998-03-13 1999-09-27 Epimmune, Inc. Hla-binding peptides and their uses
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
DE60020997T2 (de) 1999-12-06 2006-05-24 Hopital Sainte-Justine, Montreal Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CN1452634A (zh) * 2000-02-23 2003-10-29 埃皮缪纳股份有限公司 Hla结合肽及其用途
CA2420225A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
US6974574B2 (en) 2001-08-16 2005-12-13 The General Hospital Corporation Methods of inducing an HIV specific response using a Vpr-specific epitope
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
DE102005020911A1 (de) * 2005-05-04 2006-11-16 Carl Zeiss Meditec Ag Verfahren zur Messung der Änderung des Polarisationszustands von polarisierter optischer Strahlung durch eine optisch aktive Schicht eines Körpers und/oder einer Konzentration eines optisch aktiven Stoffs in der Schicht und Vorrichtung zur Durchführung des Verfahrens
US8133691B2 (en) 2005-07-06 2012-03-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Stable quantitation and detection of immune response levels with non-zero background peptides
NZ582822A (en) * 2007-07-27 2012-06-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2819416C (en) 2010-12-02 2019-04-30 Bionor Immuno As Peptide scaffold design
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
US10501499B2 (en) 2012-06-06 2019-12-10 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
CN105200010B (zh) * 2015-10-15 2019-02-12 首都医科大学附属北京佑安医院 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU2361595A (en) * 1994-04-22 1995-11-16 Sloan-Kettering Institute For Cancer Research Induction of cytotoxic t lymphocytes (ctl) using antigenic peptides and a suitable adjuvant
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells

Also Published As

Publication number Publication date
ATE296313T1 (de) 2005-06-15
CN1218406A (zh) 1999-06-02
JP4210735B2 (ja) 2009-01-21
EP0907370B1 (en) 2005-05-25
EP0907370A1 (en) 1999-04-14
CA2248667A1 (en) 1997-09-25
EP0907370A4 (en) 1999-10-20
WO1997034621A1 (en) 1997-09-25
DE69733352T2 (de) 2006-04-27
JP2002515869A (ja) 2002-05-28
AU2658897A (en) 1997-10-10
BR9708220A (pt) 2000-01-04
DE69733352D1 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
AU725550B2 (en) HLA binding peptides and their uses
CA2248667C (en) Hla-a2.1 binding peptides and their uses
US7252829B1 (en) HLA binding peptides and their uses
EP1917970B1 (en) Hla binding peptides and their uses
EP0703783B1 (en) Methods of making immunogenic hla-a2.1 binding peptides
CA2400215A1 (en) Hla binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
EP1089757B1 (en) Hla binding peptides and their uses
WO2002020616A1 (en) Hla-a2.1 binding peptides and their uses
US20030185822A1 (en) HLA-A2.1 binding peptides and their uses
EP1320377B1 (en) Hla binding peptides and their uses
US20040157780A1 (en) CTL inducing peptides from c-erb2 (HER-2/neu)
EP1767542B1 (en) HLA-A2.1 binding peptides and their uses
CA2421448A1 (en) Hla binding peptides and their uses
AU4754899A (en) HLA Binding peptides and their uses
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170321